OpenClinica to Unveil New Software Release at Global Conference
Culminating 18 months of research, development and testing, OpenClinica will formally unveil a new version of its software package—Version 3.1—at its Global Conference in Boston on May 8-9.
Ben Baumann, OpenClinica’s Director of Business Development, says the conference will feature a number of demonstration sessions designed to give attendees a live, hands-on experience with the new technology.
OpenClinica facilitates the development of new medical treatments by lowering the cost of clinical trials while raising the standards for efficiency and transparency in clinical research.
The OpenClinica Global Conference brings together users, developers, and other stakeholders from the OpenClinica community to share knowledge and best practices. The event features lectures, case studies, tutorials, panel discussions, posters, and technical demonstrations. Participants in the event represent numerous countries including China, Brazil, Germany, India, Denmark, Taiwan, Austria, Switzerland, Argentina, and the United Kingdom. Participants represent biopharmaceutical companies, device companies, contract research organizations, academic centers, and government agencies.
Kenneth A. Getz, Chairman of the Center for Information & Study on Clinical Research Participation CISCRP, and Senior Research Fellow and Assistant Research Professor at the Tufts Center for the Study of Drug Development, will be the conference’s keynote speaker. He will discuss how open source software and open communities can be a solution to challenges facing the pharmaceutical industry.
“The sustainability of drug development desperately depends on new models of innovation,” said Mr. Getz. “Innovative open source projects like OpenClinica hold tremendous promise for addressing this need,” Getz said.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
